SCHEDULE: Sands Capital Discloses 8.2% Stake in Beta Bionics

Sands Capital Life Sciences Pulse Fund II, along with its affiliates, reported a beneficial ownership of 8.2% in Beta Bionics, Inc. common stock.

Summary

• Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC, and Frank M. Sands (collectively, 'Reporting Persons') jointly filed an Amendment No. 1 to Schedule 13G.
• Reporting Persons beneficially own an aggregate of 3,570,113 shares of Beta Bionics, Inc. Common Stock.
• This ownership represents 8.2% of Beta Bionics, Inc.'s outstanding Common Stock.
• The percentage is based on 43,470,125 shares outstanding as of July 25, 2025, as reported in Beta Bionics' Form 10-Q filed on July 29, 2025.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for potential nominations under Rule 14a-11.

Sentiment

Score: 6

Explanation: A neutral to slightly positive sentiment. The filing itself is a factual disclosure of ownership, which is neutral. However, a significant stake by a reputable investment firm like Sands Capital can be perceived positively by the market as a vote of confidence, even if the filing doesn't explicitly state it.

Positives

• A significant institutional investor, Sands Capital, has taken or maintained a substantial stake in Beta Bionics, indicating confidence in the company's long-term prospects.
• The filing is an amendment, suggesting a previous disclosure, and this update confirms the continued or adjusted significant holding.

Risks

• The disclosure of a significant institutional holding, while generally positive, inherently carries the risk of potential future divestment by the investor, which could impact the company's share price.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Beta Bionics, Inc.'s future operations or financial performance.

Industry Context

The disclosure of a significant stake by Sands Capital, an investment firm with a 'Life Sciences Pulse Fund,' suggests Beta Bionics operates within the life sciences or biotechnology sector. Such institutional investments are common in growth-oriented sectors, particularly those requiring substantial capital for research, development, and commercialization.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not provide operational or financial results that can be directly compared to industry benchmarks or specific comparable companies/projects. Its significance lies in the disclosed ownership stake by a notable investment firm.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding an 8.2% stake may be viewed positively, potentially increasing investor confidence and market liquidity.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the holding is not for control purposes.

Next Steps

• This filing does not outline specific future actions or milestones for Beta Bionics, Inc. or the Reporting Persons beyond the ongoing regulatory compliance for their ownership stake.

Key Dates

Recommendation

The Schedule 13G filing indicates a significant, non-control-oriented stake by Sands Capital, a reputable investment firm. While this suggests institutional confidence in Beta Bionics, the filing itself provides no new operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates or financial results from Beta Bionics to make a more informed decision, as this filing primarily confirms an existing or adjusted ownership position.

Keywords

Beta Bionics, Sands Capital, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Life Sciences